news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

news

Ozempic-Wegovy pill may be on the way: Trial shows promising results for new weight loss tablet | Joggingvideo.com
-0.6 C
New York
Thursday, February 29, 2024

Ozempic-Wegovy pill may be on the way: Trial shows promising results for new weight loss tablet

Ozempic and Wegovy — both injectable forms of semaglutide — have become synonymous with weight loss in recent months and years. Now a new drug is on the horizon that would offer the same medication in an oral (pill) format.

Created by Novo Nordisk, the same company that makes Ozempic and Wegovy, the new drug just completed its Phase 3 clinical trials. The results were announced on Sunday at the American Diabetes Association (ADA) Scientific Session in Los Angeles, California.

The oral medication, which is indicated for type 2 diabetes or weight loss for patients with obesity, would provide an alternative to people who are not open to getting injections.

WEIGHT LOSS MEDICATIONS OZEMPIC AND WEGOVY: WHAT TO KNOW BEFORE YOU STOP TAKING THEM

“Our focus has been primarily on people with diabetes, but it turns out that the vast majority of people with type 2 diabetes also have obesity,” Gabbay explained. 

“So having a medication that can address a central issue for people with diabetes is really important — especially for those who are somewhat resistant to or concerned about doing an injection.”

DOCTORS URGE CAUTION ON DIABETES DRUGS FOR WEIGHT LOSS AFTER STUDY HIGHLIGHTS SIDE EFFECTS

“They could have [had] pre-diabetes, but they were not allowed to be enrolled in the trial if they had type 2 diabetes.”

The average amount lost by the patients was 44 pounds.

In addition to helping with weight loss, the semaglutide medication can also help to reduce cardiovascular disease in people with diabetes, Gabbay noted.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER 

“For those people who are at high risk or [who] already have cardiovascular disease, the parent drug has been shown to reduce mortality, and there’s no reason to expect that this wouldn’t be the case with the oral version,” he told Fox News Digital.

CLICK HERE TO GET THE FOX NEWS APP

“We’re pleased to see that there are new options for people with diabetes and obesity,” Gabbay said. 

“Having something that is orally available should increase the number of people who can benefit from these kinds of treatments.”

Related Articles

Stay Connected

1,520FansLike
4,561FollowersFollow
0FollowersFollow
- Advertisement -

Latest Articles